Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions] Please be advised that today's conference is being recorded.
Cellectar Biosciences Inc. (CLRB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | ||
| 3. | 0 | $0 | 0% | ||
| 4. | ADAR1 Capital Management Daniel Schneeberger | 0 | $0 | 0% | |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.99 | 10,000 | $49,900.00 | 11,638 | 2025-07-02 | Filing | |
| $4.99 | 10,000 | $49,900.00 | 12,768 | 2025-07-02 | Filing | |
| $4.99 | 5,000 | $24,950.00 | 6,418 | 2025-07-02 | Filing | |
| $0.28 | 30,000 | $8,400.00 | 83,141 | 2025-01-10 | Filing | |
| $1.04 | 25,000 | $26,000.00 | 25,000 | 2021-09-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.21 | 53 | $117.13 | 0 | 2018-11-29 | Filing | |
| $2.21 | 939 | $2,075.28 | 53 | 2018-11-29 | Filing | |
| $1.18 | 13,000 | $15,397.20 | 67,000 | 2018-03-13 | Filing | |
| $1.20 | 34,000 | $40,704.80 | 213,548 | 2018-03-12 | Filing | |
| $1.49 | 5,214 | $7,790.76 | 626,103 | 2017-11-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 56,341 | $400,585 | 0% | |
| 2. | 14,439 | $102,678 | 0% | |
| 3. | 10,500 | $74,655 | 0.02% | |
| 4. | 4,742 | $33,716 | 0% | |
| 5. | 3,620 | $25,738 | 0% |
News See All
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode. Following the presentation, there will be a question-and-answer session.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode. Following the presentation, there will be a question-and-answer session.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Call Transcript
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Call Transcript November 18, 2024Cellectar Biosciences, Inc. misses on earnings expectations.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q2 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Cellectar Biosciences Second Quarter 2024 Financial Results Call. Today’s call is being recorded.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2024 Earnings Call Transcript
Operator: Good morning and welcome to Cellectar Biosciences First Quarter 2024 Earnings Call. Today's call is being recorded.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript
Operator: Good morning. And welcome to Cellectar Biosciences 2023 Yearend Earnings Call. Today's call is being recorded.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today's conference is being recorded.
10 Best Biotech Penny Stocks To Buy Now
Like all sectors of the economy right now, the biotech sector is going through a lot of pain.
Is Cellectar Biosciences (CLRB) A Good Stock To Buy According To Hedge Funds?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September.
Billionaire Hedge Funds
